GSK4396687

Vaccine

Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

This drug's own stage for COVID-19: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
GSK4396687: this drugStage not on recordVaccine—not yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Elasomeran (Spikevax)ApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
IbuzatrelvirPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.